Ventria Bioscience's internal clinical development programs highlight our capabilities in biotherapeutics development and manufacturing optimization. We currently have two products in our formal clinical pipeline, with more in discovery and development. We have successfully completed a phase 2 clinical trial studying the safety, tolerability, and efficacy of our lead therapeutic candidate, VEN100, in the prevention of antibiotic-associated diarrhea (AAD) in high-risk patients. A phase 3 pivotal trial of VEN100 is planned to begin enrollment in 2012.
Our manufacturing facilities have been audited by leading pharmaceutical and biopharmaceutical companies and approved for producing bioreagents used in manufacturing therapeutics. Contact us to learn how you can leverage Ventria Bioscience's proven experience in clinical product development and manufacturing process optimization for your next clinical biologic product.